论文部分内容阅读
目的探讨克唑替尼和化疗在治疗间变性淋巴瘤激酶(ALK)阳性晚期非小细胞肺癌(NSCLC)患者中的临床疗效。方法选取2014年4月至2015年10月间内蒙古医科大学附属医院收治的50例NSCLC患者的临床资料,采用随机数字表法分为观察组与对照组,每组25例。观察组患者采用克唑替尼治疗,对照组患者采用多西他赛治疗。比较两组患者的临床疗效、生存质量、生存情况及不良反应。结果治疗后,观察组患者的临床疗效和卡氏(KPS)生存质量情况明显较对照组好,差异均有统计学意义(均P<0.01)。治疗前,两组患者的进展生存期(PFS)及总生存期(OS)评分比较,差异无统计学意义(P>0.05)。治疗后,观察组患者的PFS及OS评分均高于对照组,且两组患者的PFS及OS评分均较同组治疗前高,差异均有统计学意义(均P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论与常规化疗法相比,克唑替尼治疗ALK阳性晚期NSCLC患者疗效更佳,可延长患者的PFS及OS,提升患者生活质量,值得推广。
Objective To investigate the clinical efficacy of crizotinib and chemotherapy in the treatment of patients with anaplastic lymphoma kinase (ALK) -positive advanced non-small cell lung cancer (NSCLC). Methods The clinical data of 50 patients with NSCLC who were admitted to the Affiliated Hospital of Inner Mongolia Medical University from April 2014 to October 2015 were randomly divided into observation group and control group with 25 cases in each group. Patients in the observation group were treated with crizotinib, and patients in the control group were treated with docetaxel. The clinical efficacy, quality of life, survival and adverse reactions of the two groups were compared. Results After treatment, the clinical efficacy and the quality of life of KPS in the observation group were significantly better than those in the control group (all P <0.01). Before treatment, there was no significant difference in PFS and OS between the two groups (P> 0.05). After treatment, the PFS and OS scores of the observation group were higher than those of the control group. The PFS and OS scores of the two groups were significantly higher than those before treatment (all P <0.05). Two groups of patients with adverse reactions, the difference was not statistically significant (P> 0.05). Conclusion Compared with conventional chemotherapy, crizotinib is more effective in treating patients with advanced ALK-positive advanced NSCLC, which can prolong PFS and OS, and improve the quality of life of patients. It is worthy of promotion.